Purpose In the general population, lack of adherence to statin therapy remains a widespread phenomenon and an important matter of concern both in terms of cost-effectiveness and riskbenefit profile. This study aimed to evaluate the occurrence of cardiovascular events in Italian statin recipients, focussing on the relationship between degree of adherence to therapy and occurrence of events in a 3-year follow-up. Methods Our cohort consisted of all patients from Emilia Romagna (4,027,275 inhabitants) who received statin prescriptions in January-February 2005 and who were followed for up to 36 months for cardiovascular hospital admission (i.e. coronary disease, cerebrovascular accidents, peripheral arthropathy), adherence to statin treatment (proportion of days covered: ≥80%) and use of other cardiovascular drugs. The relationship between adherence and cardiovascular events was analysed by multivariate logistic regression; age, sex, other cardiovascular drugs and previous events were covariates of the model. Results Patients non-adherent to a statin regimen over the 3-year period (76% of the cohort) had higher odds of events, irrespective of risk factors, by more than 40% when compared with adherent patients. Odds of events were in particular: strongly non-adherent, adjOR =1.19 (CI95% 1.15-1.23), slightly non-adherent, adjOR =1.25 (1.21-1.30), highly variable in the amount of statins received, adjOR=1.69 (1.62-1.77). Conclusions This study shows the key role of adherence to statins in cardiovascular prevention at any level of risk. Appropriateness of statin use needs not only careful selection of patients to be treated, but also cooperation between patient and physician to ensure continued drug use whenever treatment is appropriate.
Introduction
Randomised controlled trials have clearly shown the benefits of lipid-lowering drug treatment for cardiovascular prevention, but how much these translate into actual benefit in the general population is not as well established. Whereas there is consensus on the benefits in secondary prevention [1, 2] recommendations to use statins in primary prevention are currently a matter of debate [3] [4] [5] [6] and in fact statins are used mostly in the latter setting (75% of statin recipients [7] ). Some authors cast doubt on the benefit of statins in patients with low cardiovascular risk [8] whereas others suggested the use of statins (alone or even in the socalled polypill) even in normolipidaemic subjects [4, 9, 10] .
Lack of adherence is probably the most relevant factor differentiating randomised controlled trials from clinical practice.
In the general population, lack of adherence to statin therapy remains a widespread phenomenon and, consequently, an important matter of concern both in terms of cost-effectiveness and the risk-benefit profile. We have previously shown that, among statin recipients, less than 50% were prescribed an amount of drug consistent with daily treatment and this coverage was only slightly higher in patients in secondary prevention, in those aged 50-69 years and among male subjects. Moreover, adherence significantly increased with the complexity of other cardiovascular treatments [7] . On the contrary, prescription of a highly active statin regimen (which can be used as a proxy of the severity of hypercholesterolaemia) did not correlate with coverage.
The role of adherence to statins in preventing cardiovascular events in general practice is currently under investigation from different points of view (i.e. risk-benefit and cost-benefit profile) and some investigators have already published useful experiences in different countries [11] [12] [13] [14] [15] . However, the scenario is far from complete and the evidence is still partial and insufficient to support Health Policy strategies [16] .
The aim of this study was to evaluate the occurrence of cardiovascular events in all patients treated with statins in Emilia Romagna (about 4,000,000 inhabitants), focussing on the relationship between the occurrence of events and the degree of adherence to therapy.
Materials and methods

Sources of data
Drug prescription data were retrieved from the EmiliaRomagna Regional Health Authority Database, which provides the following information for each reimbursed prescription: identification code of the drug, ATC (Anatomical Therapeutic Chemical) code, number of packages dispensed, patient code, date of prescription. The patient code allows retrieval of his/her drug history without individual identification.
We collected data of statins and other drugs used for cerebro-or cardiovascular risk prevention (i.e. antiplatelet agents, nitrates, antihypertensives, antidiabetics), prescribed by general practitioners (GPs) and reimbursed between January 2003 and February 2008 by the Health Authority of Emilia Romagna (with both the urban and the rural areas, 4,027,275 inhabitants). The following ATC codes were considered: A10-drugs used in diabetes; B01A-antithrombotic agents; C01DA-antianginal drugs (nitrates); C02, C03, C07, C08, C09-drugs used in the treatment of hypertension; C10-lipid modifying agents.
All statins are reimbursed by Italian Health Service for patients with familial hypercholesterolaemia, patients with previous cardiovascular or cerebrovascular events, or patients with a 10-year cardiovascular risk higher than 20%.
Data from hospital admissions for cardiovascular or cerebrovascular events, occurring from January 2003 to February 2008, were retrieved from the hospital discharge registry, which provides the following information: ICD-9 code (410-414: ischaemic heart disease; 430-438: cerebrovascular diseases; 440: atherosclerosis; 443: other peripheral vascular disease; 444: arterial embolism and thrombosis), type of the hospital and ward, duration of the hospital stay and patient code.
Data regarding age, sex and deaths were anonymously retrieved from vital statistics.
All the databases are managed by the Drug Policy Service of the Health Department of the Emilia-Romagna Region, which provides anonymous data by attributing an anonymous code to each patient. This code allows the record linkage of individual patient data among different databases according to the provisions of privacy rules. The protocol was approved by the institutional ethics committee. Adherence was evaluated by analysing the amount of statins received during the 3-year period:
& For each year, patients were considered "covered" if they received at least 300 tablets (allowing a tolerance of ∼20% over the 365-day period) [7] & Patients who met the above criterion throughout the 3-year follow-up were considered as "adherent"
The amount of statins was evaluated as the number of tablets purchased. In fact, the availability of different dosage strengths for each active substance allowed patients to take their daily medication as one tablet.
Statistical analyses
To evaluate the association between cardiovascular events and adherence to statin treatment, a logistic multivariate regression analysis was performed, by grouping non-adherent patients into three different categories: "strongly non-adherent", "slightly non-adherent" and "highly variable" patients (see Table 2 for definitions). Age, sex, comorbidity (diabetes, hypertension-angina-heart failure and thrombosis in the first year of follow-up) were included as covariates in the models.
Only patients surviving the 3-year follow-up period were included in the logistic analysis.
To better describe the role of the adherence in cardiovascular prevention, two different stratified models for the primary and secondary prevention groups were estimated. Patients in the secondary prevention group were those who experienced a cardiovascular event before the recruitment. The effect of adherence was assessed by a generalisation of the Mantel-Haenszel method in different subgroup samples.
The differences in subgroups were tested with Pearson's χ 2 test. A p value <0.05 was considered significant.
All analyses were performed using STATA version 10 (Stata, College Station, TX, USA) and SAS version 9.1 (SAS Institute, Cary, NC, USA).
Results
Adherence to statin regimen
The cohort of statin recipients consisted of 137,217 subjects, with a mean age of 67±10 years and 1:1 female/ male ratio (Table 1) . During the 3 years of follow-up, 6,491 subjects (5%) died. Seventy-seven percent of subjects (106,167) received prescriptions of the same statin and simvastatin was the most frequently prescribed (32% of patients), followed by atorvastatin (24%). The remaining 23% of patients were switched to another statin, especially rosuvastatin (23.6%) or atorvastatin (12.6%). Moreover, 72% received only highly active statin regimens (i.e. at dosages expected to reduce LDL-cholesterol by more than 30% [7] ).
Eighty-five percent of patients received additional cardiovascular treatments in the first year of follow-up: in particular, 77% of subjects (105,341) concomitantly received drugs for hypertension or angina or heart failure, 54% (73,963) used antithrombotics and 16% (21,530) used antidiabetics ( Table 1 ). During the remaining 2 years of follow-up, a further 2.5% of patients per year received antihypertensive prescriptions, a further 5% received antithrombotics and a further 2.5% received antidiabetics.
In our cohort, 35% did not receive statin prescriptions in the 2 previous years (new users). The proportions of patients receiving more than 300 tablets/year of statins and that of patients receiving 201-300 tablets/year were stable throughout the 3 years of follow-up (45% and 24% c Concomitant CV disorders were evaluated by the prescription of the relevant drugs in the first year of follow-up. The following ATC codes were considered: A10-drugs used in diabetes; C01DA-antianginal drugs (nitrates); C02, C03, C07, C08, C09-drugs used in the treatment of hypertension and B01A-antithrombotic agents d Patients were considered adherent when they were prescribed at least 300 doses of statins for each of the 3 years of follow-up; patients who died during follow-up were included in the non-adherent group respectively), whereas that of patients receiving 101-200 tablets decreased from 24% to 19% and that of patients taking less than 101 tablets showed an appreciable increase, from 6% in the first year to 13% in the third one. Sixty-two percent (81,666) of patients were covered for at least 1 year, 44% (60,894) for at least 2 years and 24% (32,355) for the whole 3-year period and only this last figure represents the adherent population according to our criteria (Fig. 1) .
Among the 98,371 patients who did not meet the criteria to be considered "adherent", 28% (38,328) were "slightly non-adherent", 30% (41,678) "strongly non-adherent", and 13% (18,382) "highly variable" ( Table 2 ).
Cardiovascular events
Within the whole cohort of 137,217 patients, 29% (39,708) experienced cerebro-or cardiovascular events during the 3-year follow-up (annual rate: 13%): 54% of events were represented by coronary heart disease, followed by cerebrovascular accidents (18%). (Fig. 2) . The only exception was the younger age group (<50 years), for whom the confidence interval includes 1. Moreover, for subjects older than 80 years, in both the primary and secondary prevention groups, and in patients with diabetes in the primary prevention group, the association between lack of adherence and cardiovascular events was statistically stronger than in unstratified analysis. Considering patients' prescriptions 12 months before and after the occurrence of an event, 53% of patients increased their number of tablets after the event, so that a fraction (15%) of the non-covered patients became covered in the year after the event. On the other hand, 26% of patients did not change their number of tablets and the remaining 21% even decreased it.
Discussion
In our cohort of 137,217 patients, more than three quarters of statin recipients did not adhere to drug therapy throughout the 3-year follow-up and, these patients showed more than 40% increase in cardiovascular events compared with adherent statin recipients.
Although the issue of lack of adherence to statin treatment has been already reported [7, 17] , in our opinion, a population-based cohort study is important because it attempts to translate adherence to statin regimen into actual cardiovascular benefit in unselected patients in a community setting. Some previous studies provided useful findings to clarify this topic. A study on a large Israeli cohort [18] found a strong association between the intensity of statin therapy (in terms of number of tablets/year) and improved survival, in both the primary and secondary prevention groups, even higher than that found in clinical trials (up to 45% of risk reduction). Also, a Canadian study showed the important role of adherence to statins in the prevention of both cerebrovascular events (reduction of risk: 26%) and f Reference: subjects without prescription of drugs for angina, hypertension or heart failure g Reference: subjects without prescriptions of antithrombotic agent coronary disease (18%) [11] [12] [13] . Two recent Italian studies focussed on incident statin recipients for primary prevention. On the one hand, Deambrosis et al. found a better cholesterol outcome in adherent patients, but a paradoxical association between adherence and hospitalisation for coronary events [14] . This finding was probably affected by a confounding factor, represented by the basal cardiovascular risk, which conditioned independently both adherence and hospital admissions. On the other hand, Corrao et al. found a protective role of adherence in non-fatal ischaemic heart disease (reduction of risk: 15-20%) [15] .
Our results (although not directly comparable to those of the above studies because of different parameters in outcomes and in the observed population) substantially agree on the clinical importance of continued statin use and provide a wider picture of cardiovascular outcomes in all users (both incident users and those already having treatment at recruitment).
The approach used in this study has strengths and limitations. In our opinion, one strength was represented by performing our analysis in a large community setting, including all statin recipients, no matter what the length of patients without hospital admission for a cardiovascular event in the 2 years before the recruitment. b Secondary prevention: patients with at last one hospital admission for a cardiovascular event in the 2 years before recruitment therapy before the recruitment was, and including all meaningful cardiovascular outcomes. On the one hand, the findings provided by this approach refer to prevalent statin users, whereas other studies frequently selected only incident users, which represent only a minority of overall statin recipients. On the other hand, our method intrinsically lacks completeness in prior morbidity and drug history, and could be affected by the immeasurable time bias [19] because of the lack of information on statin exposure during hospitalisations. In the worst case scenario, this bias could have generated a misclassification of 586 non-adherent subjects (0.4% of the cohort), who would pass to adherent status by considering all hospitalisation days as covered days. On the basis of these data, we found a possible overestimation of the risk of events among nonadherent patients of 6 and 8% respectively in the primary and secondary prevention groups. A further limitation was the lack of information on lipidaemia, which was an obstacle in the correct association between adherence and cardiovascular outcomes. However, information on lipidaemia would be very difficult to collect even using physicians' records. In addition, since our prescription data were obtained only from the reimbursement database, we probably excluded patients who did not meet the Italian reimbursement criteria, because they were at a lower risk of cardiovascular events. This lack of data could have caused a slight overestimation of the role of adherence in the prevention of cardiovascular events.
Moreover, a positive attitude of patients towards their own health could be a confounding factor, influencing independently both statin adherence and event occurrence, but this information is not available in administrative databases either, and these are the sources of data in our study. Only studies based on questionnaires or a primary care database could collect this data and quantify the magnitude of the "healthy adherer effect". This healthy adherer effect, has already been acknowledged by Dragomir et al. [12] , Rasmussen et al. [20] and Andersohn and Willich [21] , who stated the difficulties in its quantification. Nonetheless, a generic "healthy adherer behaviour" could have generated a tolerable overestimation of the protective effect of adherence.
Finally, because of the low frequency and the delayed onset of cardiovascular events in low-risk patients, a longer follow-up could provide further evidence in this population.
When addressing the health policy implications of our results showing the close relationship between adherence to statins and their effectiveness, the fact that 3 out of 4 of statin recipients were not adherent suggests that statin use in our community setting produces both scarce gain in terms of health and a waste of economic resources.
For efficient resource allocation, quantification of the non-adherent population to optimise overall health gain in the community is a priority [16] . Each Health Authority faces two different scenarios: first, encouraging efforts to cover a large population entails inherent problems in ensuring adherence, increased overall burden of side effects, in an attempt to reduce as much as possible the number of cardiovascular events, and second, envisaging a strategy more stringently identifying the population with a likely benefit (which implies less effort to ensure adherence, decreased overall burden of side effects, lower drug cost, but incomplete population protection from cardiovascular risk) [16] .
In the light of these potential benefits and limitations, there is debate on which strategy is better, but certainly the specific risk profile of the resident population and the availability of economic resources should guide decision-makers.
In our community setting, we interpret the paradoxically lower odds of cardiovascular events in strongly nonadherent patients as an indication that this group was at lower risk than the other non-adherent patients. Indeed, the strongly non-adherent group probably included a number of subjects who actually did not require pharmacological lipidlowering treatment. Therefore, we would not recommend measures to improve adherence in this group. Probably, efforts to improve adherence should focus on the 28% of subjects who were not strictly adherent, but received a yearly amount of drug able to cover at least 6 months (slightly non-adherent patients), and on the 13% of subjects who alternated covered years with years at very low intensity of treatment (highly variable patients). Notably, the last group showed the highest odds of cardiovascular events (about 70% higher than adherent patients).
Conclusions
This study shows the key role of adherence to statins in the prevention of cardiovascular events at any level of risk in a community setting. Appropriate use of statins needs both strict selection of patients before starting drug treatment and patient-physician cooperation for continued drug use when the treatment is appropriately started.
